Literature DB >> 11060330

Organizing cancer genetics programs: the Swiss model.

G Pichert1, R A Stahel.   

Abstract

PURPOSE: Inherited predisposition to cancer is a complex issue, and risk assessment, counseling, and management are multidisciplinary tasks. An infrastructure is needed through which clinical services may be delivered and research activities conducted.
METHODS: The Swiss Institute for Applied Cancer Research (SIAK) Network for Cancer Predisposition Testing and Counseling was established in 1999. The goals of the Network are to set common standards for clinical services, to coordinate research activities, to address psychosocial and ethical issues concerning genetic counseling and testing, and to translate the knowledge gained into medical practice.
RESULTS: An algorithm for genetic testing and counseling of the families studied by the SIAK Network centers has been established in a consensual process. Eight regional centers currently operate according to this algorithm. Furthermore, a proposal has been submitted for the setup of a Swiss databank for the characterization of BRCA1 and BRCA2 mutation patterns and the identification of potentially unique mutations in probands who seek genetic counseling and testing at the respective centers of the SIAK Network.
CONCLUSION: Our coordinated effort will ensure state-of-the-art genetic testing and counseling services in Switzerland and will allow us to acquire knowledge for appropriate risk assessment and surveillance/prevention strategies for individuals with an inherited cancer predisposition.

Entities:  

Mesh:

Year:  2000        PMID: 11060330

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  1 in total

1.  Swiss primary care physicians' knowledge, attitudes and perception towards genetic testing for hereditary breast cancer.

Authors:  Gabriella Pichert; Daniel Dietrich; Peter Moosmann; Marcel Zwahlen; Rolf Arno Stahel; André-Pascal Sappino
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.